Webinar by Antoni Ribas
When the cancer becomes an enabler of an antitumor immune response
Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, USA
The research by Antoni Ribas, MD, PhD focuses on laboratory and clinical studies to address primary and acquired resistance to melanoma therapies, and in the development of gene-engineered adoptive T cell transfer therapies for cancer. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is the immediate-past president of the American Association for Cancer Research (AACR). He is an elected Fellow of the AACR Academy, the Royal Academy of Medicine of Catalonia, the American Society of Clinical Investigation, and the US National Academy of Medicine.